Chinese Biotech, Investments Are on Track to Face New US Curbs
A technician works inside a production laboratory for cell therapies in Nanjing, China.
Photographer: Qilai Shen/BloombergThe US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US investment in Chinese AI and advanced computing.
The Biosecure Act targeting Chinese biotech as well as the FIGHT China Act targeting US investments in technologies with military applications were both included in the latest version of the National Defense Authorization Act agreed to by House and Senate negotiators over the weekend.